ahlam1399
07-21-2016, 04:14 PM
BRIEF-Advaxis? AXAL Receives Fast Track Designation by FDA
* Advaxis' AXAL receives fast track designation by the FDAas adjuvant therapy for high-risk locally advanced cervicalcancer patientsSource text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=Ct4jwnR6_yU:dhhmxTvl4qI:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Ct4jwnR6_yU:dhhmxTvl4qI:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=Ct4jwnR6_yU:dhhmxTvl4qI:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Ct4jwnR6_yU:dhhmxTvl4qI:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=Ct4jwnR6_yU:dhhmxTvl4qI:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/Ct4jwnR6_yU
* Advaxis' AXAL receives fast track designation by the FDAas adjuvant therapy for high-risk locally advanced cervicalcancer patientsSource text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=Ct4jwnR6_yU:dhhmxTvl4qI:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Ct4jwnR6_yU:dhhmxTvl4qI:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=Ct4jwnR6_yU:dhhmxTvl4qI:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Ct4jwnR6_yU:dhhmxTvl4qI:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=Ct4jwnR6_yU:dhhmxTvl4qI:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/Ct4jwnR6_yU